All News

Physiomics to give an oral presentation on developments of the Virtual Tumour platform in drug resistance at the Seventh American Conference on Pharmacometrics (“ACoP7”) Physiomics plc (AIM: PYC), the Oxford, UK based systems biology Company, is pleased to announce that it is participating in the ACoP7 Meeting 2017, taking place at the Hyatt Regency Bellevue, Washington on 24-26 October 2016. Dr David Orrell, Principal Consultant, will...

Read More

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce the appointment of Hybridan LLP as sole broker with effect from 28th December 2016. WH Ireland Limited will continue to act as the Company’s NOMAD. Please click here for full information....

Read More

The Company announces that it has completed a placing, conditional only on Admission, to raise £555,000.00 from the issue of 2,220,000,000 new ordinary shares of 0.004p each ("Ordinary Shares") at a price of 0.025p per share, through Hybridan LLP (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealing is expected to commence on 28th...

Read More

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today published and posted to shareholders a circular in relation to a forthcoming General Meeting, due to be held at the Company’s registered office, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford, OX4 4GA at 10:00 a.m. on 7th September 2016. The directors will propose at...

Read More

Physiomics plc (AIM: PYC). Following the announcement on 31st March 2016 of its intention to acquire BioMoti Limited, the Company is pleased to announce that it has signed a Share Purchase Agreement with BioMoti. The acquisition remains conditional on the Company completing a successful placing to raise a minimum of £1m to develop the new joint company’s drug discovery and development pipeline. Please click here for...

Read More

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce the appointment of Hybridan LLP as joint broker with immediate effect. Please click here for full information.  ...

Read More

Dr Christophe Chassagnole, COO and Dr Eric Fernandez, Project Leader will be both present at PAGE 2016. Dr Fernandez will present on modelling radiation therapy in the poster session I on the 8th of June at 10:20 and Dr Christophe Chassagnole will present on the newest development of the Virtual Tumour in drug resistance in the poster session II on the 8th of June at 15:10. Please click here...

Read More

Physiomics is pleased to announce that it has signed further extensions to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012.  The 6th extension will cover predicting optimal regimens for follow-up compounds and in vitro to in vivo translation, whereas the 7th extension will predict optimal regimens for a candidate in an additional cancer indication Read more...

Read More

The Company announces that Anthony Clayden, of Strategic Finance Director Limited, has been appointed Head of Finance to lead the financial management and provide company secretarial services with effect from 1 May 2016. This is not a board position, and Anthony is not being appointed a director or officer of Physiomics. At the same time the existing Financial Controller and Company Secretary, Liz King will...

Read More